Telmisartan and Insulin Resistance in HIV (TAILoR): protocol for a dose-ranging phase II randomised open-labelled trial of telmisartan as a strategy for the reduction of insulin resistance in HIV-positive individuals on combination antiretroviral therapy
Sudeep Pushpakom(University of Liverpool), Munir Pirmohamed(University of Liverpool), Saye Khoo(University of Liverpool), Thomas Jaki(MRC Biostatistics Unit), Paula Williamson(University of Liverpool), Graham J. Kemp(John Radcliffe Hospital), John Whitehead(Lancaster City Council), Jiten Vora(University of Liverpool), Claire Taylor(University of Liverpool), Marta García‐Fiñana(University of Liverpool), Ruwanthi Kolamunnage‐Dona(University of Liverpool), Catherine Spowart(University of Liverpool)
Cited by 29
Related Papers
Drug repurposing: progress, challenges and recommendations
|Nature Reviews Drug Discovery|2018|4.6k
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
|The Lancet|2020|3.7k
Systematic Review of the Empirical Evidence of Study Publication Bias and Outcome Reporting Bias
|PLoS ONE|2008|1.5k
Methotrexate and Cyclosporine Compared with Cyclosporine Alone for Prophylaxis of Acute Graft versus Host Disease after Marrow Transplantation for Leukemia
|New England Journal of Medicine|1986|1.5k
HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin
|Nature Genetics|2009|1.1k